🚀 VC round data is live in beta, check it out!
Concord Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Concord Biotech and similar public comparables like Zhejiang Ausun, Guilin Sanjin, Idorsia, ORIC Pharmaceuticals and more.
Concord Biotech Overview
About Concord Biotech
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
Founded
1984
HQ
Employees
1.6K
Website
Sectors
Financials (LTM)
EV
$1B
Concord Biotech Financials
Concord Biotech reported last 12-month revenue of $126M and EBITDA of $45M.
In the same LTM period, Concord Biotech generated $96M in gross profit, $45M in EBITDA, and $32M in net income.
Revenue (LTM)
Concord Biotech P&L
In the most recent fiscal year, Concord Biotech reported revenue of $140M and EBITDA of $59M.
Concord Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $126M | XXX | $140M | XXX | XXX | XXX |
| Gross Profit | $96M | XXX | $93M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $45M | XXX | $59M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 42% | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 39% | XXX | XXX | XXX |
| Net Profit | $32M | XXX | $44M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 31% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Concord Biotech Stock Performance
Concord Biotech has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Concord Biotech's stock price is $11.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.5% | XXX | XXX | XXX | $0.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialConcord Biotech Valuation Multiples
Concord Biotech trades at 9.4x EV/Revenue multiple, and 26.1x EV/EBITDA.
EV / Revenue (LTM)
Concord Biotech Financial Valuation Multiples
As of April 19, 2026, Concord Biotech has market cap of $1B and EV of $1B.
Equity research analysts estimate Concord Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Concord Biotech has a P/E ratio of 37.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 9.4x | XXX | 8.4x | XXX | XXX | XXX |
| EV/EBITDA | 26.1x | XXX | 19.9x | XXX | XXX | XXX |
| EV/EBIT | 29.8x | XXX | 21.6x | XXX | XXX | XXX |
| EV/Gross Profit | 12.3x | XXX | 12.7x | XXX | XXX | XXX |
| P/E | 37.9x | XXX | 28.1x | XXX | XXX | XXX |
| EV/FCF | 36.4x | XXX | 82.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Concord Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Concord Biotech Margins & Growth Rates
Concord Biotech's revenue in the last 12 month grew by 23%.
Concord Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Concord Biotech's rule of 40 is 55% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Concord Biotech's rule of X is 80% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Concord Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | (11%) | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 42% | XXX | XXX | XXX |
| EBITDA Growth | 34% | XXX | (25%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 80% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Concord Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Concord Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Ausun | XXX | XXX | XXX | XXX | XXX | XXX |
| Guilin Sanjin | XXX | XXX | XXX | XXX | XXX | XXX |
| Idorsia | XXX | XXX | XXX | XXX | XXX | XXX |
| ORIC Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Concord Biotech M&A Activity
Concord Biotech acquired XXX companies to date.
Last acquisition by Concord Biotech was on XXXXXXXX, XXXXX. Concord Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Concord Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialConcord Biotech Investment Activity
Concord Biotech invested in XXX companies to date.
Concord Biotech made its latest investment on XXXXXXXX, XXXXX. Concord Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Concord Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Concord Biotech
| When was Concord Biotech founded? | Concord Biotech was founded in 1984. |
| Where is Concord Biotech headquartered? | Concord Biotech is headquartered in India. |
| How many employees does Concord Biotech have? | As of today, Concord Biotech has over 1K employees. |
| Who is the CEO of Concord Biotech? | Concord Biotech's CEO is Ankur Vaid. |
| Is Concord Biotech publicly listed? | Yes, Concord Biotech is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Concord Biotech? | Concord Biotech trades under CONCORDBIO ticker. |
| When did Concord Biotech go public? | Concord Biotech went public in 2023. |
| Who are competitors of Concord Biotech? | Concord Biotech main competitors are Zhejiang Ausun, Guilin Sanjin, Idorsia, ORIC Pharmaceuticals. |
| What is the current market cap of Concord Biotech? | Concord Biotech's current market cap is $1B. |
| What is the current revenue of Concord Biotech? | Concord Biotech's last 12 months revenue is $126M. |
| What is the current revenue growth of Concord Biotech? | Concord Biotech revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Concord Biotech? | Current revenue multiple of Concord Biotech is 9.4x. |
| Is Concord Biotech profitable? | Yes, Concord Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Concord Biotech? | Concord Biotech's last 12 months EBITDA is $45M. |
| What is Concord Biotech's EBITDA margin? | Concord Biotech's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Concord Biotech? | Current EBITDA multiple of Concord Biotech is 26.1x. |
| What is the current FCF of Concord Biotech? | Concord Biotech's last 12 months FCF is $32M. |
| What is Concord Biotech's FCF margin? | Concord Biotech's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Concord Biotech? | Current FCF multiple of Concord Biotech is 36.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.